PL2613809T3 - Sposób łagodzenia niepożądanych zdarzeń leków z zastosowaniem kwasów tłuszczowych omega-3 jako pozajelitowego podłoża terapeutycznego leku - Google Patents

Sposób łagodzenia niepożądanych zdarzeń leków z zastosowaniem kwasów tłuszczowych omega-3 jako pozajelitowego podłoża terapeutycznego leku

Info

Publication number
PL2613809T3
PL2613809T3 PL11760887T PL11760887T PL2613809T3 PL 2613809 T3 PL2613809 T3 PL 2613809T3 PL 11760887 T PL11760887 T PL 11760887T PL 11760887 T PL11760887 T PL 11760887T PL 2613809 T3 PL2613809 T3 PL 2613809T3
Authority
PL
Poland
Prior art keywords
omega
fatty acids
events
parenteral therapeutic
vehicle
Prior art date
Application number
PL11760887T
Other languages
English (en)
Inventor
David F. Driscoll
Original Assignee
Stable Solutions Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stable Solutions Llc filed Critical Stable Solutions Llc
Publication of PL2613809T3 publication Critical patent/PL2613809T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL11760887T 2010-09-10 2011-09-12 Sposób łagodzenia niepożądanych zdarzeń leków z zastosowaniem kwasów tłuszczowych omega-3 jako pozajelitowego podłoża terapeutycznego leku PL2613809T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/923,257 US20110071090A1 (en) 2009-03-11 2010-09-10 Method of mitigating adverse drug events using omega-3-fatty acids as a parenteral therapeutic drug vehicle
PCT/US2011/001567 WO2012033538A1 (en) 2010-09-10 2011-09-12 Method of mitigating adverse drug events using omega-3 fatty acids as a parenteral therapeutic drug vehicle
EP11760887.7A EP2613809B1 (en) 2010-09-10 2011-09-12 Method of mitigating adverse drug events using omega-3 fatty acids as a parenteral therapeutic drug vehicle

Publications (1)

Publication Number Publication Date
PL2613809T3 true PL2613809T3 (pl) 2020-01-31

Family

ID=44675802

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11760887T PL2613809T3 (pl) 2010-09-10 2011-09-12 Sposób łagodzenia niepożądanych zdarzeń leków z zastosowaniem kwasów tłuszczowych omega-3 jako pozajelitowego podłoża terapeutycznego leku

Country Status (15)

Country Link
US (1) US20110071090A1 (pl)
EP (1) EP2613809B1 (pl)
JP (1) JP6000251B2 (pl)
KR (1) KR101923192B1 (pl)
CN (1) CN103200965B (pl)
BR (1) BR112013004440B1 (pl)
CA (1) CA2808406C (pl)
ES (1) ES2760997T3 (pl)
IL (1) IL223955A (pl)
MX (1) MX336347B (pl)
PL (1) PL2613809T3 (pl)
PT (1) PT2613809T (pl)
RU (2) RU2013115923A (pl)
TW (1) TWI505837B (pl)
WO (1) WO2012033538A1 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8993625B2 (en) 2009-03-11 2015-03-31 Stable Solutions Llc Method of mitigating adverse drug events using omega-3 fatty acids as a parenteral therapeutic drug vehicle
US9034389B2 (en) 2009-03-11 2015-05-19 Stable Solutions Llc Omega-3 enriched fish oil-in-water parenteral nutrition emulsions
US10052352B2 (en) 2011-06-15 2018-08-21 Stable Solutions Llc Therapeutic application of parenteral krill oil
EP2720701B1 (en) * 2011-06-15 2017-08-09 Stable Solutions Llc Therapeutic application of parenteral krill oil
JP6359517B2 (ja) * 2012-03-30 2018-07-18 サンシリオ アンド カンパニー, インコーポレイテッドSancilio & Company, Inc. ω−３脂肪酸エステル組成物
DK2858496T3 (da) 2012-05-10 2023-07-24 Solutex Na Llc Olier med anti-inflammatorisk aktivitet, som indeholder naturlige specialiserede pro-afhjælpningsmediatorer og deres forløbere
EP2861227A4 (en) 2012-06-17 2016-01-27 Matinas Biopharma Inc OMEGA-3 PENTAIC ACID COMPOSITIONS AND METHODS OF USE
CN103054799B (zh) * 2012-10-11 2015-04-08 北京泰德制药股份有限公司 一种盐酸胺碘酮注射乳剂及其制备方法
CA2894183A1 (en) * 2012-12-06 2014-06-12 Matinas Biopharma, Inc. Omega-3 pentaenoic acid compositions and methods of use
CA2905671A1 (en) * 2013-03-13 2014-09-18 Matinas Biopharma Inc. Omega-3 pentaenoic acid compositions and methods of use
WO2015113987A1 (en) * 2014-01-28 2015-08-06 Fresenius Kabi Deutschland Gmbh Composition comprising epa and dha triglycerides for parenteral administration
EP3099287A1 (en) * 2014-01-28 2016-12-07 Fresenius Kabi Deutschland GmbH Composition comprising epa and dha ethylester for parenteral administration
US10653703B2 (en) 2015-09-03 2020-05-19 Solutex Na Llc Compositions comprising omega-3 fatty acids, 17-HDHA and 18-HEPE and methods of using same
EP3525781B2 (en) 2016-10-11 2024-04-24 Fresenius Kabi Deutschland GmbH Composition comprising epa and dha for an enhanced efficacy of anticancer agents
KR20180052080A (ko) * 2016-11-08 2018-05-17 차의과학대학교 산학협력단 비스테로이드 항염증제의 부작용 방지용 조성물 및 부작용이 나타나지 않은 항염용 조성물

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5118493A (en) * 1986-05-02 1992-06-02 Brigham And Women's Hospital Composition having reduced nephrotoxocity comprising a fatty acid containing component and cyclosporine
DE3734147C2 (de) * 1987-10-09 1998-10-29 Braun Melsungen Ag Isotone omega-3-fettsäurenhaltige Fettemulsion und ihre Verwendung
GB8819110D0 (en) * 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
US5780451A (en) * 1994-04-01 1998-07-14 Abbott Laboratories Nutritional product for a person having ulcerative colitis
US5574065A (en) * 1994-04-21 1996-11-12 Clintec Nutrition Co. Method and composition for normalizing injury response
DE69612011T3 (de) * 1995-11-24 2010-02-18 Unilever N.V. Zusammensetzung auf basis von fischöl
AU701736B2 (en) * 1995-11-28 1999-02-04 B. Braun Melsungen Ag Hydrolysis-optimized lipid emulsions and use thereof
IT1277953B1 (it) * 1995-12-21 1997-11-12 Sigma Tau Ind Farmaceuti Composizione farmaceutica contenente l-carnitina o una alcanoil l- carnitina e un acido poliinsaturo della serie 3-omega utile per
WO1999029316A1 (en) * 1997-12-10 1999-06-17 Severson, Mary, L. Pharmaceutical compositions containing an omega-3 fatty acid oil
IT1304406B1 (it) * 1998-10-21 2001-03-19 Danital Italia S R L Preparazione per la veicolazione di principi attivi basata su acidigrassi polinsaturi del gruppo omega 3.
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US6380253B1 (en) * 2000-01-05 2002-04-30 Efa Sciences Llc Method of stabilizing and potentiating the action of anti-angiogenic substances
GB0012597D0 (en) * 2000-05-25 2000-07-12 Astrazeneca Ab Formulation
EP1539104A4 (en) * 2000-12-29 2005-06-15 Univ Columbia USE OF IV EMULSIONS OF DIFFERENT TRIGLYCERIDE COMPOSITION, PARTICLE SIZE AND APOLIPOPROTEIN E FOR TARGETED TISSUE DELIVERY OF HYDROPHOBIC COMPOUNDS
EP1279400A1 (en) * 2001-07-25 2003-01-29 Target Hit sa Modifying the fatty acid composition of cell membranes of organs and tissues
AU2003291667A1 (en) * 2002-10-31 2004-06-07 Alza Corporation Pharmaceutical formulation providing an increased bioavailability of hydrophobic drugs
US7323206B1 (en) * 2003-03-04 2008-01-29 B. Braun Medical Inc. Reagents and methods for all-in-one total parenteral nutrition for neonates and infants
WO2005046669A1 (en) * 2003-11-12 2005-05-26 Children's Medical Center Corporation Treatment and prevention of liver disease associated with parenteral nutrition (pn)
US8557861B2 (en) * 2004-09-28 2013-10-15 Mast Therapeutics, Inc. Low oil emulsion compositions for delivering taxoids and other insoluble drugs
WO2008036353A2 (en) * 2006-09-19 2008-03-27 The Trustees Of Columbia University In The City Of New York Omega-3 diglyceride emulsions
US8241672B2 (en) * 2009-03-11 2012-08-14 Stable Solutions Llc Omega-3 enriched fish oil-in-water parenteral nutrition emulsions
US8993625B2 (en) * 2009-03-11 2015-03-31 Stable Solutions Llc Method of mitigating adverse drug events using omega-3 fatty acids as a parenteral therapeutic drug vehicle

Also Published As

Publication number Publication date
PT2613809T (pt) 2019-10-18
EP2613809B1 (en) 2019-07-24
KR101923192B1 (ko) 2018-11-28
BR112013004440A2 (pt) 2016-05-31
CN103200965B (zh) 2016-06-08
JP2013537192A (ja) 2013-09-30
JP6000251B2 (ja) 2016-09-28
MX2013002725A (es) 2013-04-08
CN103200965A (zh) 2013-07-10
TW201219057A (en) 2012-05-16
MX336347B (es) 2016-01-15
RU2013115923A (ru) 2014-10-20
BR112013004440B1 (pt) 2021-02-09
ES2760997T3 (es) 2020-05-18
TWI505837B (zh) 2015-11-01
IL223955A (en) 2016-02-29
KR20130135839A (ko) 2013-12-11
CA2808406A1 (en) 2012-03-15
CA2808406C (en) 2021-03-16
RU2017126315A3 (pl) 2020-10-30
WO2012033538A1 (en) 2012-03-15
RU2017126315A (ru) 2019-01-31
US20110071090A1 (en) 2011-03-24
EP2613809A1 (en) 2013-07-17

Similar Documents

Publication Publication Date Title
PL2613809T3 (pl) Sposób łagodzenia niepożądanych zdarzeń leków z zastosowaniem kwasów tłuszczowych omega-3 jako pozajelitowego podłoża terapeutycznego leku
IL234104A (en) METHOD FOR PREPARING Medium-length fatty acids with triglycerides
SG2013092010A (en) Production of omega-amino fatty acids
PL2409963T3 (pl) Zastosowanie pochodnych wielonienasyconych kwasów tłuszczowych jako leki
EP3040407A4 (en) Method for producing high purity omega-3 fatty acid ethyl ester
GB201223210D0 (en) Method of attaching a dental component to a dental implant
EP2444389A4 (en) PROCESS FOR THE PREPARATION OF 2-FLUOROACRYLIC ESTERS
IL233413A (en) Methods for Producing Acrylic Pinkol Acid 4-Chloro-2-Fluoro-3-Converted-Phenylboron
PL2697348T3 (pl) Proces estryfikacji autokatalitycznej kwasów tłuszczowych
EP2789601A4 (en) PROCESS FOR PREPARING A FATTY ACID MONOGLYCERIDE-BASED MIXTURE
EP2560633B8 (en) Intravenous omega-3 fatty acid compositions & method of use
PT2774910T (pt) Enantiómeros de derivados de 2-hidróxi de ácidos gordos
SI2906587T1 (sl) Metode in sestave za izboljšano proizvodnjo maščobnih kislin in njihovih derivatov
IL229617A0 (en) Healthy foodstuffs containing ethyl esters of fatty acids, especially of flax oil, and a method for their production
IL213354A0 (en) Alpha-derivatives of cis-monounsaturated fatty acids intended for use as a drug
ZA201400886B (en) Method for synthesizing an omega-amino acid or ester from a monousaturated fatty acid or ester
EP2673254A1 (de) Ein verfahren zur destillation von fettsäureestern
IL230623A (en) Methods for Isolating 4-Chloro-2-Fluoro-3-Converted-Phenylboron Acid
IL256784A (en) Method for preparing a fatty acid derivative
EP2399976A4 (en) Method for producing fatty acid alkyl ester
PL2478081T3 (pl) Sposób oczyszczania estrów alkilowych kwasów tłuszczowych silnie obciążonych produktami zmydlania
GB201104698D0 (en) Improved method for the production of conjugated polyunsaturated fatty acids with heterogenous catalysts
GB201102962D0 (en) Improved method for the production of conjugated polyunsaturated fatty acids with heterogenous catalysts
GB201019961D0 (en) Improved method for the production of conjugated polyunsaturated fatty acids with heterogenous catalysts
PL395611A1 (pl) Sposób otrzymywania estrów trimetylopropanu i kwasów tluszczowych